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Genetic testing for mutations in BRCA1 and BRCA2 is available in Canada for women with a significant family history of breast cancer.
For the majority of tested women, a BRCA1 or BRCA2 mutation is not found, and counselling regarding breast cancer risk is based
on the review of the pedigree. In this prospective study, we estimate breast cancer risks in women with a family history of breast
cancer and for whom the proband tested negative for a mutation in BRCA1 or BRCA2. Families with two or more breast cancers
under the age of 50 years, or with three cases of breast cancer at any age, and who tested negative for a BRCA1 or BRCA2 mutation
were identified. Follow-up information on cancer status was collected on all first-degree relatives of breast cancer cases. The
standardised incidence ratios (SIRs) for breast cancer were calculated by dividing the observed numbers of breast cancer by the
expected numbers of breast cancers, based on the rates in the provincial cancer registries. A total of 1492 women from 365 families
were included in the analyses. The 1492 first-degree relatives of breast cancer cases contributed 9109 person-years of follow-up.
Sixty-five women developed breast cancer, compared to 15.2 expected number (SIR¼4.3). The SIR was highest for women under
the age of 40 (SIR¼14.9) years and decreased with increasing age. However, the absolute risk was higher for women between the
age of 50 and 70 (1% per year) years than for women between 30 and 50 (0.4% per year) years of age. There was no elevated risk
for ovarian, colon or any other form of cancer. Women with a significant family history of breast cancer (ie, two or more breast
cancers under the age of 50 years, or three or more breast cancers at any age), but who test negative for BRCA mutations have
approximately a four-fold risk of breast cancer. Women in these families may be candidates for tamoxifen chemoprevention and/or
intensified breast screening with an MRI.
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A woman’s breast cancer risk is increased if she has a first-degree
relative with breast cancer at a young age, or if she has more than
one relative with breast cancer (Claus et al, 1990; Cancer,
Collaborative Group on Hormonal Factors in Breast Cancer
(CGoHFiB), 2001). The Collaborative Group on Hormonal Factors
in Breast Cancer (Cancer, Collaborative Group on Hormonal
Factors in Breast Cancer (CGoHFiB), 2001) analysed data from 52
epidemiological studies and reported on the risks of breast cancer
in the first-degree relatives. The estimated cumulative incidence of
breast cancer up to the age of 80 years for individuals with zero,
one, and two first-degree relatives were 7.8, 13.3, and 21.1%,
respectively (Cancer, Collaborative Group on Hormonal Factors in
Breast Cancer (CGoHFiB), 2001).
For women with a significant family history of breast cancer,
genetic testing for mutations in BRCA1 and BRCA2 is available
throughout Canada and elsewhere. Approximately, 25% of familial
breast cancer patients carry a mutation in one of the two breast
cancer genes (Shih et al, 2002; Simard et al, 2007). Hence, the
majority of women with a family history of breast cancer will
receive a negative genetic test result. For these women, counselling
regarding breast cancer risk estimation is difficult and is based on
the examination of the pedigree and the evaluation of other risk
factors. It is unclear to what extent their breast cancer risk is
raised. In this study, we estimate the breast cancer risks for women
with a strong family history of breast cancer, but tested negative
for a mutation in BRCA1 or BRCA2.
MATERIALS AND METHODS
Sample
Eligible subjects were drawn from a database of families who had
received testing for BRCA1 and BRCA2 mutations in Ontario and
British Columbia, but tested negative. Each family contained two
or more breast cancers diagnosed under the age of 50 years, or
three cases of breast cancer diagnosed at any age. These families
were assessed for genetic risk at one of the two Canadian centres
between 1993 and 2003. In each family, at least one woman affected
with breast cancer had been tested and was found not to carry a
BRCA1 or BRCA2 mutation. Testing methods varied between the
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scentres and over time; but in each case, all coding exons of BRCA1
and BRCA2 were screened using a combination of PTT, DGGE,
dHPLC, and direct sequencing.
Methods
Eligible individuals within these families included all female first-
degree relatives of the breast cancer cases who were over the age of
18 years at the time when the pedigree was drawn. Each pedigree
was dated on the day in which the information was collected. The
proband (first person from family to make contact with genetics
centre) from each family was contacted by telephone. The family
history was updated through a telephone interview. Information
was collected on all female first-degree relatives of all breast cancer
cases within the family. Collected data included age, cancer status,
prophylactic surgery, and vital status. In the event that the
proband was not familiar with the family history in sufficient
detail, we asked her to identify a second person in the family who
was able to provide additional details. The study received ethics
approval from both participating centres.
Analysis
All first-degree relatives of women affected with breast cancer in
the family were identified. These women were considered as a
cohort of at-risk women, and the risk of breast and other cancers
were estimated in the cohort using survival analysis. Each woman
was considered to be at risk of cancer from the date of the original
pedigree ascertainment to the earliest of (1) the date of the follow-
up telephone call; (2) the date at which cancer was diagnosed (if
diagnosed with cancer), or (3) the date of death (if deceased). For
each study subject, the total number of person-years at risk was
calculated. Person-years at risk were then categorised according to
age group, in 5-year age groupings. The annual cancer risk was
estimated for the entire cohort, for each of the 5-year groupings, by
dividing the number of cancers observed by the total number of
person-years at risk, and multiplying by 10
5. The expected rates for
Ontario and for British Columbia were obtained from the registry
data recorded in Cancer Incidence in Five Continents (volume VII).
The SIR was estimated from the ratio of the observed rate to the
expected rate. We estimated the cumulative incidence of cancer in
the cohort of first-degree relatives by applying the observed age-
specific rates to a theoretical cohort of women from 25 to 75 years
of age.
Results
Among the 474 families, there was a total of 874 breast cancers
(mean: 51.0, range: 25–90) were identified in the pedigrees at
baseline. We identified 1599 first-degree relatives of the 874
women with breast cancer and who did not have breast cancer at
the time of the initial ascertainment. Data were missing for 423
women. For 107 women, the proband who has tested was
unaffected and they were excluded. The remaining 1492 were
members of a family in which an affected woman (i.e., with a
previous diagnosis of cancer) had undergone testing for BRCA1
and BRCA2. The analysis is restricted to these 1492 women from
365 families. The mean age of these women at the time of pedigree
drawing was 48.2 years (range: 17–99) and at the time of the
follow-up interview was 54.3 years (range: 24–101). The mean time
from genetic testing in the proband to the time of follow-up was
6.1 years (range: 1–10). The 1492 first-degree relatives contributed
9109 person-years of follow-up.
A total of 65 women developed breast cancer, compared to an
expected number of 15.2. The actuarial risk of breast cancer in the
entire cohort was 0.7% per year, or roughly 40% over the lifetime
(Figure 1). The annual risk increased from 0.4% per year for
women between 25 and 40 years of age to approximately 1% per
year for women over the age of 50 years (Table 1). The expected
number of breast cancers were determined from age-specific
cancer incidence rates recorded in Cancer Incidence in Five
Continents (Vol. VIII, IARC). The standardised incidence ratios
(SIRs) for breast cancer were calculated by dividing the observed
numbers of breast cancer by the expected numbers of breast
cancer. Table 1 presents the SIRs by age at time of baseline (i.e.,
genetic testing in proband). The SIRs decreased with increasing
age (Table 2), ranging from 14.9 at age of 25–39 years to 3.0 at age
60 years or older.
Subanalyses were conducted based on the number of breast
cancers in relatives (Table 3). The observed number of breast
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Figure 1 Cumulative incidence of breast cancer.
Table 1 Standardised incidence ratios (SIRs) of breast cancer by age
Age at baseline
Variables Total 25  30  35  40  45  50  55  60  65  70  75  80  85+
Frequency 1492 171 152 176 214 167 144 108 86 63 76 56 44 35
Person-years 9109 738 794 1032 1215 1183 1003 737 579 467 438 364 291 268
New breast cancers
Observed (N)
65 2 4 5 6 6 10 7 5 6 7 4 1 2
New breast cancers
expected (N)
16.49 0.05 0.16 0.53 1.23 2.06 2.17 1.85 1.64 1.60 1.61 1.45 1.15 0.99
Rate per 10
5 observed 713.6 271.0 503.8 484.5 493.8 507.2 997.0 949.8 863.6 1284.8 1598.2 1098.9 343.6 746.3
Rate per 10
5 expected 181.0 6.8 20.8 51.5 101.4 173.9 216.6 250.8 284 342.7 366.9 397.6 393.7 369.1
SIR 3.9 40.1 30.3 9.4 5 2.9 4.1 3.8 3.1 3.8 5 2.8 0.9 2.1
95% CI 3.1–5.0 11.0–146 7.8–51 4.3–23.4 2.3–10.9 1.3–6.2 2.5–8.4 1.9–8.0 1.3–7.3 1.7–8.2 2.1–9.0 1.1–7.3 0.2–5.1 0.6–7.3
P-value o0.0001 0.02 0.002 0.002 0.007 0.05 0.0008 0.009 0.05 0.02 0.006 0.10 0.92 0.41
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scancers was significantly greater than expected for all subgroups.
There was no increase in SIR with increasing number of relatives
with breast cancer. A separate analysis was conducted on the basis
of the number of first-degree relatives with breast cancer
diagnosed at age of 50 years or younger (Table 4). Again, there
were no differences according to the number of relatives with
early-onset breast cancer. The SIRs were also calculated for other
cancers (Table 5). There was no significant difference in observed
vs expected number of ovarian cancers (P¼0.82) or colon cancers
(P¼0.79). The excess cancer risk was limited to breast cancer.
DISCUSSION
In Ontario and British Columbia, women with a strong family
history of breast cancer are eligible for genetic testing for BRCA1
and BRCA2. However, for most families who exhibit the
characteristics of hereditary transmission of breast cancer, a
BRCA1 or BRCA2 mutation is not detected. For women in these
families, questions remain about their breast cancer risk and the
appropriate risk management strategies. In this study, we report
that women with a family history of breast cancer (i.e., two or more
breast cancers under the age of 50 years, or three or more breast
cancers at any age) are at elevated risk of breast cancer. In many
centres, a negative BRCA report is reported as ‘non-informative’
(i.e., no mutation can be detected). This implies that the risk of
cancer is most likely higher than those with a ‘true negative’ (i.e.,
those with a negative genetic test result in a family with a known
BRCA1 or BRCA2 mutation) genetic test result. However, it is
unclear to what extent a woman’s cancer risk is increased when
faced with a ‘non-informative’ genetic test result. Our study
confirms that women with a family history of breast cancer do
have an increased risk of breast cancer; however, it should be
noted that there was no evidence for an increase in the risk of
ovarian or any other cancer. Surveillance and preventive measures
should be directed towards breast cancer.
In an earlier study, Kauff et al (2005) reported on breast and
ovarian cancer risk in 165 BRCA1 and BRCA2 mutation-negative
hereditary breast cancer families (Kauff et al, 2005). They reported
an SIR for breast cancer that was similar to ours (SIR¼3.1, 95%
CI¼1.9–4.9; Po0.001). Again, no significantly increased risk was
seen for ovarian cancer (SIR¼1.5, 95% CI¼0.02–8.5; P¼0.5).
However, age-specific risks were not presented (likely due to the
small sample size). In addition, 23% of the probands in their study
were unaffected with breast cancer. This may explain why the SIR
for breast cancer reported by Kauff et al. (2005) was lower than
ours (SIR¼4.3).
In our study, women younger than the age of 40 years had the
greatest elevation in breast cancer risk, compared to age-specific
general population breast cancer risks. After the age of 40 years,
the breast cancer relative risks were less extreme. Olsen et al (1999)
reported SIRs for breast cancer in mothers and sisters of 2840
probands with early-onset breast cancer (under the age of 40 years;
mothers: SIR¼2.0; 95% CI¼1.8–2.2; sisters: SIR¼2.6; 95%
CI¼2.1–3.2; Olsen et al, 1999). The SIR was influenced by the
age of the female relative, with younger women having higher risks
Table 4 Standardised incidence ratios (SIRs) of breast cancer by the number of first-degree relatives diagnosed with breast cancer of p50 years
Observed
(rate per 10
5)
Expected
(rate per 10
5) SIRs 95% CI P-value
No first-degree relative with breast cancer of p50 years (N¼607) 25 (678.2) 7.11 (192.9) 3.52 2.38–5.19 o0.0001
One first-degree relative with breast cancer of p50 years (N¼677) 27 (646.9) 6.29 (150.7) 4.29 2.95–6.25 o0.0001
Two or more first-degree relatives with breast cancer of p50 years (N¼207) 12 (965.4) 3.08 (247.8) 3.90 2.23–6.81 0.0006
Table 5 Standardised incidence ratios (SIRs) of other cancers
Cancer type Observed (rate per 10
5) Expected (rate per 10
5) SIRs 95% CI P-value
Breast cancer 65 (713.6) 16.49 (181.0) 3.94 3.09–5.02 o0.0001
Ovarian cancer 2 (21.5) 2.34 (23.3) 0.85 0.23–3.12 0.82
Colon cancer 4 (43.1) 5.04 (48.9) 0.79 0.31–2.04 0.79
All cancers 98 (1083.7) 54.14 (552.5) 1.81 1.49–2.21 o0.0001
All cancers except breast cancer 33 (364.9) 37.78 (385.8) 0.87 0.62–1.23 0.42
Skin cancer is not included as a cancer.
Table 2 Standardised incidence ratios (SIRs) of breast cancer by age group
Age group Observed (rate per 10
5) Expected (rate per 10
5) SIRs 95% CI P-value
25–39 11 (42.9) 0.74 (2.9) 14.9 8.30–26.6 o0.0001
40–49 12 (50.0) 3.29 (13.7) 3.64 2.09–6.38 0.001
50–59 17 (97.7) 4.02 (23.1) 4.23 2.64–6.77 o0.0001
60 and above 25 (103.9) 8.44 (35.1) 2.96 2.01–4.37 o0.0001
Table 3 Standardised incidence ratios (SIRs) of breast cancer by the number of relatives diagnosed with breast cancer at any age
Number of relatives diagnosed
with breast cancer
Mean age at
baseline (range)
Observed
(rate per 10
5)
Expected
(rate per 10
5) SIRs 95% CI P-value
1o r2( n¼182) 45.9 (17–85) 9 (790.9) 1.88 (165.2) 4.79 2.52–9.10 0.001
3( N¼479) 49.6 (18–92) 23 (779.1) 5.57 (188.7) 4.13 2.75–6.20 o0.0001
4 or more (N¼830) 47.9 (18–99) 32 (638.3) 9.02 (179.9) 3.55 2.51–5.01 o0.0001
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sof breast cancer. Rawal et al (2006) reported similar findings
among 31235 first-degree relatives of 8807 probands with early-
onset breast cancer (SIR¼2.3: 95% CI¼2.0–2.7). (Rawal et al,
2006). In the largest study, the Cancer, Collaborative Group on
Hormonal Factors in Breast Cancer (CGoHFiB) (2001) estimated
the relative risk for women with three or more first-degree
relatives with breast cancer to be 3.9 (95% CI¼2.0–7.5). This
estimate is very similar to that for the women in our cohort
(SIR¼4.3). However, we estimate the lifetime risk for breast
cancer to be 40% compared to 21% in the Collaborative Group
study.However, in these studies, BRCA1 and BRCA2 testing were
not conducted and mutation carriers were not excluded.
Recently, there has been much interest in generating and
applying polygenic risk models for risk assesment in breast cancer;
these are based on developing a profile of genotypes for a number
of single nucleotide polymorphisms. For example, Pharoah et al
(2008) propose that a seven-gene profile can help explain a
proportion of the heritability of breast cancer in the population
and can be used to assign women to different levels of risk. The
approach has been criticised by others as having a limited ability
to discriminate risk in women in the general population (Gail,
2008). The odds ratios associated with a ‘high-risk’ profile in the
polygenic model tend to be approximately 1.5 compared to the
odds ratio of 4 that we observed, based on the family history alone.
In our opinion, family history is a much more useful tool than are
polygenic tests and more effort should be concentrated on refining
risk estimates by conducting more studies such as ours. Greater
attention should be paid by the medical community in order that a
detailed and accurate family history of breast cancer is obtained on
all women.
For women with a BRCA1 or BRCA2 mutation, current options
include breast screening, prophylactic surgery, and chemopreven-
tion. However, in women from high-risk families in which a
BRCA1 or BRCA2 mutation is not detected, it is unclear if the
screening and risk reduction options offered to these women
should be the same as for women with a BRCA1 or BRCA2
mutation. MRI has been shown to be effective in detecting small
breast cancers in BRCA1 and BRCA2 mutation carriers (Warner
et al, 2004; Leach et al, 2005; Sardanelli et al, 2007). The American
Cancer Society recommends an annual MRI screening to women
with a BRCA mutation, to women with a first-degree relative with a
BRCA mutation (but untested), and to women with a lifetime risk
of 20–25% or greater. Therefore, on the basis of this study, women
in a hereditary breast cancer family without a BRCA mutation may
qualify for MRI screening based on their lifetime risk of breast
cancer. We estimate the lifetime risk of breast cancer in these
women to be approximately 40%, or roughly one-half of a BRCA1
or BRCA2 mutation carrier. Therefore, when counselling women
from families, such as these, breast screening using MRI should be
considered.
Tamoxifen is another option. In the National Surgical Adjuvant
Breast and Bowel Project P-1 Study, tamoxifen reduced the risk of
invasive breast cancer by 49% in women at high risk (Fisher et al,
1998). High risk was defined as having a breast cancer risk of
greater than 1.66% in the next 5 years. All of the women in this
study met this criterion; from 40 to 45 years of age, the risk for
cancer was 2.5% and from 50 to 55 years of age it was
approximately 5%. Therefore, tamoxifen should be presented as
an option for women in these high-risk families without a BRCA
mutation. It would be of interest to know the estrogen-receptor
status of the newly diagnosed breast cancers in our study to better
estimate the potential for tamoxifen to decrease breast cancer risk.
The principal strength of our study is that this is a prospective
cohort and the risk estimates were based on cancers diagnosed
after the family was ascertained. This strategy eliminates the
possibility of ascertainment bias, which is often a concern when
risk estimates are based on family histories obtained at the time
the family is identified. A second strength of our study is that we
have excluded families with a known BRCA1 or BRCA2 mutation,
and therefore our risk estimates should be valid for women who
are referred for genetic testing and who receive a negative test
result. There are limitations to our study. All cancers that were
documented were self-reported and were not confirmed by
pathology report. The genetic testing was limited to the proband
and the incident cases of cancer in the study did not have genetic
testing. It is possible that, in some cases, the proband was a
sporadic case in a family where a mutation was present. It is also
possible that we missed a small number of BRCA mutations.
However, given that we saw no excess risk of ovarian cancer in the
study, it is unlikely that this is an important factor. We excluded
423 of 1599 potential study subjects (26%), because the proband
did not have information on their clinical and/or vital status. In
general, these were more distant relatives. However, if the proband
selectively included relatives with breast cancer, then this selection
bias might result in a spuriously elevated SIR.
In conclusion, women from high-risk breast cancer families in
which a BRCA1 or BRCA2 mutation can not be found need to be
counselled about their increased risk for breast cancer. Although
this risk is not as high as that for BRCA1 and BRCA2 mutation
carriers, it is significantly higher than the general population risk
and appropriate breast screening, and prevention should be
recommended.
ACKNOWLEDGEMENTS
This study was funded by the Canadian Breast Cancer Foundation
(Ontario Chapter). Dr Metcalfe is supported by a New Investigator
Award from the Canadian Institutes of Health Research and the
Ontario Women’s Health Council.
REFERENCES
Cancer, Collaborative Group on Hormonal Factors in Breast Cancer
(CGoHFiB) (2001) Familial breast cancer: collaborative reanalysis of
individual data from 52 epidemiological studies including 58 209 women
with breast cancer and 101 986 women without the disease. The Lancet
358: 1389–1399
Claus EB, Risch NJ, Thompson WD (1990) Age at onset as an indicator of
familial risk of breast cancer. Am J Epidemiol 131: 961–972
Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M,
Cronin WM, Vogel V, Robidoux A, Dimitrov N, Atkins J,
Daly M, Wieand S, Tan-Chiu E, Ford L, Wolmark N, NSABBPI (1998)
Tamoxifen for prevention of breast cancer: report of the National
Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst
90: 1371–1388
Gail MH (2008) Discriminatory accuracy from single-nucleotide poly-
morphisms in models to predict breast cancer risk. J Natl Cancer Inst
100: 1037–1041
Kauff ND, Mitra N, Robson ME, Hurley KE, Chuai S, Goldfrank D,
Wadsworth E, Lee J, Cigler T, Borgen PI, Norton L, Barakat RR, Offit K
(2005) Risk of ovarian cancer in BRCA1 and BRCA2 mutation-negative
hereditary breast cancer families. J Natl Cancer Inst 97: 1382–1384
Leach MO, Boggis CR, Dixon AK, Easton DF, Eeles RA, Evans DG, Gilbert
FJ, Griebsch I, Hoff RJ, Kessar P, Lakhani SR, Moss SM, Nerurkar A,
Padhani AR, Pointon LJ, Thompson D, Warren RM (2005) Screening
with magnetic resonance imaging and mammography of a UK
population at high familial risk of breast cancer: a prospective
multicentre cohort study (MARIBS). Lancet 365: 1769–1778
Breast cancer risks in mutation-negative women
KA Metcalfe et al
424
British Journal of Cancer (2009) 100(2), 421–425 & 2009 Cancer Research UK
G
e
n
e
t
i
c
s
a
n
d
G
e
n
o
m
i
c
sOlsen JH, Seersholm N, Boice Jr JD, Kruger Kjaer S, Fraumeni Jr JF
(1999) Cancer risk in close relatives of women with early-onset
breast cancer—a population-based incidence study. Br J Cancer 79:
673–679
Pharoah PD, Antoniou AC, Easton DF, Ponder BA (2008) Polygenes, risk
prediction, and targeted prevention of breast cancer. N Engl J Med 358:
2796–2803
Rawal R, Bertelsen L, Olsen JH (2006) Cancer incidence in first-degree
relatives of a population-based set of cases of early-onset breast cancer.
Eur J Cancer 42: 3034–3040
Sardanelli F, Podo F, D’Agnolo G, Verdecchia A, Santaquilani M, Musumeci
R, Trecate G, Manoukian S, Morassut S, de Giacomi C, Federico M,
Cortesi L, Corcione S, Cirillo S, Marra V, Cilotti A, Di Maggio C, Fausto
A, Preda L, Zuiani C, Contegiacomo A, Orlacchio A, Calabrese M,
Bonomo L, Di Cesare E, Tonutti M, Panizza P, Del Maschio A (2007)
Multicenter comparative multimodality surveillance of women at
genetic-familial high risk for breast cancer (HIBCRIT study): interim
results. Radiology 242: 698–715
Shih HA, Couch FJ, Nathanson KL, Blackwood MA, Rebbeck TR,
Armstrong KA, Calzone K, Stopfer J, Seal S, Stratton MR, Weber BL
(2002) BRCA1 and BRCA2 mutation frequency in women evaluated in a
breast cancer risk evaluation clinic. J Clin Oncol 20: 994–999
Simard J, Dumont M, Moisan AM, Gaborieau V, Malouin H, Durocher F,
Chiquette J, Plante M, Avard D, Bessette P, Brousseau C, Dorval M,
Godard B, Houde L, Joly Y, Lajoie MA, Leblanc G, Lepine J, Lesperance
B, Vezina H, Parboosingh J, Pichette R, Provencher L, Rheaume J, Sinnett
D, Samson C, Simard JC, Tranchant M, Voyer P, Easton D, Tavtigian SV,
Knoppers BM, Laframboise R, Bridge P, Goldgar D (2007) Evaluation of
BRCA1 and BRCA2 mutation prevalence, risk prediction models and a
multistep testing approach in French-Canadian families with high risk of
breast and ovarian cancer. J Med Genet 44: 107–121
Warner E, Plewes DB, Hill KA, Causer PA, Zubovits JT, Jong RA, Cutrara
MR, DeBoer G, Yaffe MJ, Messner SJ, Meschino WS, Piron CA, Narod SA
(2004) Surveillance of BRCA1 and BRCA2 mutation carriers with
magnetic resonance imaging, ultrasound, mammography, and clinical
breast examination. Jama 292: 1317–1325
Breast cancer risks in mutation-negative women
KA Metcalfe et al
425
British Journal of Cancer (2009) 100(2), 421–425 & 2009 Cancer Research UK
G
e
n
e
t
i
c
s
a
n
d
G
e
n
o
m
i
c
s